Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics

Ionis Pharmaceuticals, Inc. (IONS): $46.11

1.85 (+4.18%)

POWR Rating

Component Grades














  • Quality is the dimension where IONS ranks best; there it ranks ahead of 96.89% of US stocks.
  • The strongest trend for IONS is in Growth, which has been heading up over the past 179 days.
  • IONS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

IONS Stock Summary

  • IONS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 232.04 -- higher than 89.27% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for IONS is currently 167.82, higher than 97.2% of US stocks with positive operating cash flow.
  • Of note is the ratio of Ionis Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 9.43% of US stocks have a lower such ratio.
  • Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are ATRA, FGEN, RAPT, NTLA, and RNA.
  • IONS's SEC filings can be seen here. And to visit Ionis Pharmaceuticals Inc's official web site, go to

IONS Valuation Summary

  • IONS's price/sales ratio is 8.2; this is 115.79% higher than that of the median Healthcare stock.
  • IONS's price/sales ratio has moved down 11.1 over the prior 243 months.
  • Over the past 243 months, IONS's price/sales ratio has gone down 11.1.

Below are key valuation metrics over time for IONS.

Stock Date P/S P/B P/E EV/EBIT
IONS 2021-08-31 8.2 9.6 -10.4 -32.9
IONS 2021-08-30 8.0 9.5 -10.2 -32.4
IONS 2021-08-27 8.1 9.6 -10.3 -32.8
IONS 2021-08-26 8.0 9.4 -10.1 -32.2
IONS 2021-08-25 8.1 9.6 -10.3 -32.7
IONS 2021-08-24 8.2 9.7 -10.4 -33.0

IONS Growth Metrics

    Its 4 year price growth rate is now at 61.87%.
  • Its 4 year net cashflow from operations growth rate is now at 2050%.
  • The 5 year net cashflow from operations growth rate now stands at 2050%.
IONS's revenue has moved down $122,208,000 over the prior 15 months.

The table below shows IONS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 810.456 30.799 -28.597
2021-09-30 660.731 -74.911 -593.481
2021-06-30 687.717 -29.694 -541.959
2021-03-31 707.504 -11.186 -492.929
2020-12-31 729.264 35.892 -451.286
2020-09-30 932.664 215.847 73.401

IONS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IONS has a Quality Grade of C, ranking ahead of 48.06% of graded US stocks.
  • IONS's asset turnover comes in at 0.277 -- ranking 161st of 682 Pharmaceutical Products stocks.
  • EDIT, MYMD, and VSTM are the stocks whose asset turnover ratios are most correlated with IONS.

The table below shows IONS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.277 0.982 -0.099
2021-06-30 0.269 0.983 -0.073
2021-03-31 0.262 0.983 -0.051
2020-12-31 0.250 0.984 -0.031
2020-09-30 0.298 0.990 0.050
2020-06-30 0.306 0.992 0.063

IONS Price Target

For more insight on analysts targets of IONS, see our IONS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.82 Average Broker Recommendation 1.82 (Hold)

IONS Stock Price Chart Interactive Chart >

Price chart for IONS

IONS Price/Volume Stats

Current price $46.11 52-week high $46.15
Prev. close $44.26 52-week low $25.04
Day low $43.83 Volume 1,057,300
Day high $46.14 Avg. volume 1,090,235
50-day MA $37.89 Dividend yield N/A
200-day MA $34.79 Market Cap 6.54B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio

Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Latest News Stream

Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream

Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Analysts Are More Bearish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Than They Used To Be

One thing we could say about the analysts on Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) - they aren't optimistic...

Yahoo | February 25, 2022

Ionis (IONS) Q4 Earnings & Revenues Beat Estimates, Stock Up

Teaser: Ionis (IONS) beats Q4 earnings and sales estimates. Stock rises.

Yahoo | February 25, 2022

Company News for Feb 25, 2022

Companies in The News Are: AEP,ATHM,IONS,DISH

Yahoo | February 25, 2022

Ionis PharmaceuticalsEPS of $1.41, revenue of $440M beats by $155.92M

Ionis Pharmaceuticals press release (NASDAQ:IONS): Q4 EPS of $1.41 may not be comparable to consensus of $0.31. Revenue of $440M (+51.7% Y/Y) beats by $155.92M. FY22 Guidance: Revenue to be greater than $575M vs. $659.54M consensus. Net Loss to be less than $275M...

Seeking Alpha | February 24, 2022

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q4 2021 Results - Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (IONS) Q4 2021 Results Earnings Conference Call February 24, 2022, 11:30 AM ET Company Participants Jennifer Capuzelo - Director of Investor Relation Brett Monia - Founder & CEO Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President & Chief Development Officer Eric Swayze -...

SA Transcripts on Seeking Alpha | February 24, 2022

Read More 'IONS' Stories Here

IONS Price Returns

1-mo 26.19%
3-mo 31.29%
6-mo 40.24%
1-year 18.69%
3-year -32.63%
5-year -1.39%
YTD 51.53%
2021 -46.18%
2020 -6.41%
2019 11.75%
2018 7.48%
2017 5.16%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.8163 seconds.